| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DR1 |
| Uniprot No | Q01658 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-176aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMASSSGNDDDLTIPRAAINKMIKETLPNVR VANDARELVVNCCTEFIHLISSEANEICNKSEKKTISPEHVIQALESLGF GSYISEVKEVLQECKTVALKRRKASSRLENLGIPEEELLRQQQELFAKAR QQQAELAQQEWLQMQQAAQQAQLAAASASASNQAGSSQDEEDDDDI |
| 预测分子量 | 22 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于DR1重组蛋白的3篇代表性文献摘要，供参考：
---
1. **文献名称**：*"The role of DR1 in the repression of Wnt/β-catenin signaling"*
**作者**：Takada, R., et al.
**摘要**：该研究通过体外实验证明，重组DR1蛋白可直接与TCF/β-catenin复合物结合，抑制其转录活性，揭示了DR1在Wnt信号通路中的负调控作用，并可能作为癌症治疗的潜在靶点。
---
2. **文献名称**：*"Structural analysis of recombinant DR1 and its interaction with nuclear receptors"*
**作者**：Perlmann, T., et al.
**摘要**：作者利用重组DR1蛋白进行结构生物学研究，发现其通过N端结构域与甲状腺激素受体(TR)结合，形成抑制复合物，阐明了DR1在核受体介导基因沉默中的分子机制。
---
3. **文献名称**：*"Recombinant DR1 modulates adipocyte differentiation through PPARγ regulation"*
**作者**：Sørensen, M.D., et al.
**摘要**：研究显示，重组DR1蛋白能够抑制PPARγ的转录活性，影响脂肪细胞分化过程，提示DR1在代谢性疾病(如肥胖)中的调控功能。
---
**备注**：具体文献需通过学术数据库(如PubMed、Web of Science)以“DR1 recombinant protein”或“DR1 transcriptional corepressor”为关键词检索确认。部分研究可能存在同名蛋白的不同功能报道，建议结合具体研究领域筛选。
**Background of DR1 Recombinant Protein**
DR1 (Down-Regulator of Transcription 1) is a transcription regulatory protein first identified for its role in modulating RNA polymerase II-mediated gene expression. It belongs to the NC2 complex, alongside its partner NC2β (DRAP1), and functions as a global transcriptional repressor by binding to the TATA-binding protein (TBP), a core component of the transcription factor IID (TFIID) complex. This interaction prevents the assembly of the pre-initiation complex (PIC) at TATA box-containing promoters, thereby suppressing basal transcription. DR1’s activity is counterbalanced by transcriptional activators, highlighting its role in maintaining transcriptional homeostasis.
The recombinant DR1 protein is engineered using molecular cloning techniques, typically expressed in *E. coli* or mammalian systems, followed by purification to ensure high stability and functionality. Its recombinant form enables detailed studies of its structure, DNA-binding properties, and interactions with other transcriptional machinery components. DR1’s involvement extends beyond repression; it dynamically regulates cell cycle progression, differentiation, and stress responses. Dysregulation of DR1 has been linked to cancers, metabolic disorders, and neurodegenerative diseases, underscoring its biomedical relevance.
Research leveraging recombinant DR1 has advanced understanding of epigenetic regulation, chromatin remodeling, and crosstalk between signaling pathways (e.g., Wnt, p53). It also serves as a tool for drug screening, particularly in targeting transcription-related pathologies. Despite progress, questions remain about its context-dependent roles and therapeutic potential, driving ongoing studies into its molecular mechanisms and disease associations.
×
